Buscar en
Revista Española de Anestesiología y Reanimación (English Edition)
Toda la web
Inicio Revista Española de Anestesiología y Reanimación (English Edition) Impact of corticosteroid therapy on the survival of critical COVID-19 patients a...
Journal Information
Vol. 69. Issue 2.
Pages 120-121 (February 2022)
Vol. 69. Issue 2.
Pages 120-121 (February 2022)
Letter to the Director
Full text access
Impact of corticosteroid therapy on the survival of critical COVID-19 patients admitted into an intensive care unit
Impacto de la terapia con corticoides en la supervivencia de los pacientes críticos con COVID-19 ingresados en una unidad de cuidados intensivos
A. González-Castro
Corresponding author

Corresponding author.
, E. Cuenca Fito, A. Fernández, P. Escudero Acha, J.C. Rodríguez Borregán, Y. Peñasco
Servicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, Spain
This item has received
Article information
Full Text
Download PDF
Figures (1)
Full Text

The potential benefit of corticosteroids in the treatment of sepsis or acute respiratory distress syndrome has been evaluated in numerous clinical trials, but their effect on mortality remains controversial. Villar et al. recently demonstrated the efficacy of dexamethasone in patients with acute respiratory distress syndrome of various causes1.

Most early studies in corticosteroids for COVID-19 in the context of the current pandemic have been of low quality. However, data from the RECOVERY trial2 boosted confidence in the positive effect of corticosteroids on mortality in COVID-19 patients who require mechanical ventilation.

In light of these findings, we conducted a retrospective study of all patients admitted to our ICU for SARS-CoV-2 between 15 March and 5 December 2020 in order to analyse the impact of corticosteroid treatment on short-term survival (28 days). Corticosteroid use was recorded as a binary variable (yes or no) if patients received at least 40 mg of methylprednisolone or its equivalent over a period of at least 5 days for the purpose of treating inflammation associated with viral pneumonia.

We performed a descriptive analysis of the sample, followed by a 28-day Kaplan–Meier survival analysis using the time to death variable. Both survival curves were compared using the log-rank test.

A total of 254 patients were admitted over the study period. Twenty-eight patients with unconfirmed SARS-CoV-2 were excluded from the study, leaving 228 patients for analysis, of whom 122 received corticosteroid treatment and 106 did not.

The patients who received corticosteroid treatment were older (difference of 4 years; 95% CI: 0.47–7.53; p = 0.02) and had a higher body mass index (p = 0.03). No differences were found between groups in terms of baseline PaO2/FiO2 (p = 0.34) or in the need for mechanical ventilation during ICU stay.

The use of corticosteroids during ICU stay was associated with a significantly greater probability of survival at 28 days (HR: 1.8; 95% CI: 1.04–3.2).

Finally, the Kaplan–Meier survival curve showed statistically significant greater 28-day survival (log-rank p = 0.0345) in the group of patients who received corticosteroid treatment (Fig. 1).

Figure 1.

Survival curve (Kaplan–Meier) showing 28-day survival in the study groups.

The dashed line shows patients treated with corticosteroid therapy. The solid line shows survival in patients not treated with corticosteroids.


During this pandemic, many patients have received a wide variety of experimental therapies in all manner of combinations, often with minimal scientific evidence for their efficacy, and in such a haphazard fashion that any evaluation of their effect is difficult. The situation, according to some authors, has led to doctors squandering decades of progress in evidence-based medicine out of a desperate desire to “do something” to tackle a new challenge.

The open-label, randomized RECOVERY trial in over 2000 patients treated with corticosteroids vs. over 4000 patients who received standard treatment is one of the most robust studies in the potential impact of corticosteroids on the evolution of patients with SARS-CoV-2 infection. The results showed, among other things, that dexamethasone (6 mg daily) significantly reduced mortality in patients on mechanical ventilation, but not in patients with no respiratory failure. Despite the questionable methodology used, the results precipitated the announcement that corticosteroids were the standard treatment for COVID-193.

However, a recent meta-analysis (with pooled data from 7 studies) reported that the positive effect on mortality disappeared when data from the RECOVERY trial were excluded, indicating that these data were overweighted in the meta-analysis4. Clearly, due to the heterogeneity of the trials performed to date (compounds, dose, patient severity, time of administration, etc.), the results published must be interpreted with caution.

Therefore, although our data show better survival in patients treated with corticosteroids, more powerful studies are needed to clarify which patients will benefit most from this therapy. The administration of corticosteroids can be harmful, insofar as they appear to delay viral shedding and promote superinfections and hyperglycemia5.


This manuscript has not received any funding.

Conflict of interests

All authors acknowledge that they have no conflict of interest.

J. Villar, C. Ferrando, D. Martínez, A. Ambrós, T. Muñoz, J.A. Soler, et al.
Dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.
Lancet Respir Med, 8 (2020), pp. 267-276
The RECOVERY Collaborative Group.
Dexamethasone in hospitalized patients with COVID-19—preliminary report.
N Engl J Med, 384 (2021), pp. 693-704
F. Lamontagne, T. Agoritsas, H. Macdonald.
A living WHO guideline on drugs for COVID-19.
BMJ, 370 (2020), pp. m3379
The WHO Rapid Evidence Appraisal for COVID-19 therapies (REACT) working group.
Association between systemic corticosteroids administration and mortality among critically ill patients with Covid-19: a meta-analysis.
JAMA, 324 (2020), pp. 1330-1341
L. Zhu, Z.G. She, X. Cheng, J.J. Qin, X.J. Zhang, J. Cai, et al.
Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes.
Cell Metab, 31 (2020), pp. 1068-1077

Please cite this article as: González-Castro A, Cuenca Fito E, Fernández A, Escudero Acha P, Rodríguez Borregán JC, Peñasco Y. Impacto de la terapia con corticoides en la supervivencia de los pacientes críticos con COVID-19 ingresados en una unidad de cuidados intensivos. Rev Esp Anestesiol Reanim. 2022;69:120–121.

Copyright © 2021. Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
No mostrar más